Series A Rounds H1 2014: Fewer Deals, Comparable Money
This article was originally published in Start Up
The money raised in Series A financings for biopharma, medtech, and diagnostics start-ups is down 8% from the same period last year, but the number of deals is down even more dramatically.
You may also be interested in...
Biopharma, medtech and diagnostics start-ups raised a whopping 51% more Series A money in the first half of 2015 than during the same period last year, and the number of deals was way up too.
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
Start-ups raised $893.9 million in Q2 2014, a 25% drop from last quarter’s record-setting $1.18 billion. Metabolic disease was the most prevalent therapeutic category involved in alliances; seven acquisitions were signed, five in the biopharma sector.